Crescendo Health, a provider of a clinical research data management platform, secured an initial $3.4 million investment from early-stage investors, including Define Ventures and the founders and CEOs of well-known organizations.
With new funds, Crescendo Health plans to scale its services throughout the life sciences industry and develop new software apps that will enable its clients to research the longitudinal effects of treatments and track outcomes over time. The company’s clients include healthcare organizations, biopharma companies, medical device manufacturers, and contract research organizations.
Crescendo Health was founded in 2021 with a mission to transform how patient health data is collected and used to advance clinical research. Working with researchers from many different types of healthcare organizations, including biopharma, medical device manufacturers, and contract research organizations, Crescendo Health is unlocking access to traditionally siloed health data for patients and clinical research sponsors, allowing them to better understand the long-term outcomes of new treatments.
Commenting on the funding news, Sam Roosz, co-founder and CEO of Crescendo Health, said: “Patients participating in clinical trials generate valuable health data throughout their healthcare journey, so researchers shouldn’t be limited to information gathered in the four walls of a research clinic. However, to date, these external real-world data elements weren’t accessible to trial sponsors at scale, which is why we’re building the machinery and support required to change the paradigm.”
“We are working towards a future where research is seamlessly integrated with routine clinical care, making participation easy and accessible for patients from all backgrounds,” added Sam Roosz.
Clinical trial/research startups
Healthcare technology companies focused on providing clinical trial/research data management solutions have attracted $2 billion in funding to date, according to our funding database. More recently, Lokavant, a provider of clinical trial intelligence solutions from planning to execution, raised $21 million in equity funding led by Edison Partners with participation from Roivant Sciences. In another deal, Vial Health Technology, a startup whose technology and services are designed to help biotechnology companies run faster and more efficient clinical trials, raised $67 million in Series B funding led by General Catalyst with participation from Byers Capital, BoxGroup, and other investors.
Click here to read more about the latest digital health funding news…
